dr. mims on fda approval of ivosidenib in patients with aml
Published 6 years ago • 366 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
0:47
dr. winer discusses the fda approval of ivosidenib in aml
-
4:01
fda d.i.s.c.o. burst edition: fda approval of tibsovo (ivosidenib) in combination with azacitidin...
-
3:01
fda d.i.s.c.o. burst edition: fda approval of tibsovo (ivosidenib) for adult patients with previo...
-
3:31
fda d.i.s.c.o. burst edition: fda approval of tibsovo (ivosidenib) for patients with relapsed or ...
-
2:54
cost-effectiveness of azacitidine and ivosidenib in elderly patients with newly diagnosed idh1m aml
-
2:57
targeting idh mutations for the treatment of aml
-
4:19
molecular characterization of patients in agile: azacitidine ivosidenib or placebo in idh1m aml
-
8:00
claridhy phase iii trial of ivosidenib in cca
-
1:29
dr. steensma on midostaurin for patients with aml
-
2:08
the impact of idh mutations on the outcomes of patients with aml & inhibitors under investigation
-
4:20
enasidenib’s role in idh-mutant acute myeloid leukemia
-
5:02
results from agile: ivosidenib-azacitidine vs azacitidine-placebo in patients with idh1m aml
-
3:39
ivosidenib plus azacitidine for midh1 newly diagnosed aml
-
6:41
idh1/2 inhibitors for aml
-
6:53
ivosidenib for advanced idh1-mutated cca
-
1:42
dr. faderl gives an overview of novel therapies for aml
-
0:50
update on the pimms trial of ivosidenib for patients with idh1-mutated ccus
-
6:35
idh1/2 inhibitors in aml
-
3:26
what is the agile study? research for aml patients with the idh1 mutation